Fig. 1: Bevacizumab reduced the CD31+Ang2+ vessel density.

a Representative immunofluorescence for CD31 and Ang2 pre- and post-bevacizumab (images from paired samples of same patient); scale bar = 50 µm. Quantitative analyses of TNBC vessels (b–d).